

Marc A Judson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4628302/publications.pdf>

Version: 2024-02-01

289
papers

17,627
citations

14614

66
h-index

16127

124
g-index

325
all docs

325
docs citations

325
times ranked

10664
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. <i>Heart Rhythm</i> , 2014, 11, 1304-1323. | 0.3 | 1,077 |
| 2 | Practice Guidelines for Diseases Caused by <i>Aspergillus</i> . <i>Clinical Infectious Diseases</i> , 2000, 30, 696-709. | 2.9 | 757 |
| 3 | Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis—State of the Art: Cystic Fibrosis Foundation Consensus Conference. <i>Clinical Infectious Diseases</i> , 2003, 37, S225-S264. | 2.9 | 658 |
| 4 | Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 795-802. | 2.5 | 629 |
| 5 | A Case Control Etiologic Study of Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1324-1330. | 2.5 | 612 |
| 6 | Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, e26-e51. | 2.5 | 521 |
| 7 | A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis. <i>New England Journal of Medicine</i> , 2000, 342, 756-762. | 13.9 | 490 |
| 8 | Large-Scale Multi-omic Analysis of COVID-19 Severity. <i>Cell Systems</i> , 2021, 12, 23-40.e7. | 2.9 | 438 |
| 9 | A Concise Review of Pulmonary Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 573-581. | 2.5 | 426 |
| 10 | T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 892-899. | 2.9 | 369 |
| 11 | Cardiac sarcoidosis. <i>American Heart Journal</i> , 2009, 157, 9-21. | 1.2 | 326 |
| 12 | Treatment of Sarcoidosis With Infliximab. <i>Chest</i> , 2005, 127, 1064-1071. | 0.4 | 292 |
| 13 | The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014, 31, 19-27. | 0.2 | 273 |
| 14 | Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. <i>European Respiratory Journal</i> , 2008, 31, 1189-1196. | 3.1 | 271 |
| 15 | Endobronchial Ultrasound for the Diagnosis of Pulmonary Sarcoidosis. <i>Chest</i> , 2007, 132, 1298-1304. | 0.4 | 257 |
| 16 | Sarcoidosis in America. Analysis Based on Health Care Use. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1244-1252. | 1.5 | 257 |
| 17 | ERS clinical practice guidelines on treatment of sarcoidosis. <i>European Respiratory Journal</i> , 2021, 58, 2004079. | 3.1 | 248 |
| 18 | Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. <i>JAMA Neurology</i> , 2018, 75, 1546. | 4.5 | 247 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Thalidomide for Chronic Sarcoidosis. <i>Chest</i> , 2002, 122, 227-232. | 0.4 | 202 |
| 20 | The Diagnostic Pathway to Sarcoidosis*. <i>Chest</i> , 2003, 123, 406-412. | 0.4 | 198 |
| 21 | Pharmacotherapy for pulmonary sarcoidosis: A delphi consensus study. <i>Respiratory Medicine</i> , 2010, 104, 717-723. | 1.3 | 180 |
| 22 | Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. <i>European Respiratory Journal</i> , 2014, 44, 1296-1307. | 3.1 | 177 |
| 23 | Health-Related Quality of Life of Persons With Sarcoidosis. <i>Chest</i> , 2004, 125, 997-1004. | 0.4 | 170 |
| 24 | The Clinical Features of Sarcoidosis: A Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 63-78. | 2.9 | 167 |
| 25 | Sarcoidosis: A comprehensive review and update for the dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 699.e1-699.e18. | 0.6 | 161 |
| 26 | Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1076-1082. | 0.5 | 143 |
| 27 | MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. <i>Clinical Infectious Diseases</i> , 2014, 58, 1219-1226. | 2.9 | 142 |
| 28 | Presenting characteristics as predictors of duration of treatment in sarcoidosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 307-315. | 0.2 | 139 |
| 29 | The Treatment of Lupus Pernio. <i>Chest</i> , 2009, 135, 468-476. | 0.4 | 139 |
| 30 | Drug-Induced Sarcoidosis-Like Reactions. <i>Chest</i> , 2018, 154, 664-677. | 0.4 | 131 |
| 31 | Neurosarcoidosis. <i>Neurologist</i> , 2010, 16, 2-15. | 0.4 | 129 |
| 32 | Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , 2018, 66, 1678-1686. | 2.9 | 129 |
| 33 | The Diagnosis of Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2008, 29, 415-427. | 0.8 | 125 |
| 34 | Two year prognosis of sarcoidosis: the ACCESS experience. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2003, 20, 204-11. | 0.2 | 122 |
| 35 | Treatment of Corticosteroid-Resistant Neurosarcoidosis With a Short-Course Cyclophosphamide Regimen. <i>Chest</i> , 2003, 124, 2023-2026. | 0.4 | 120 |
| 36 | Challenges in Cardiac and Pulmonary Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1878-1901. | 1.2 | 119 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | An Approach to the Treatment of Pulmonary Sarcoidosis With Corticosteroids. <i>Chest</i> , 1999, 115, 1158-1165. | 0.4 | 108 |
| 38 | Sarcoidosis: A comprehensive review and update for the dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 719.e1-719.e10. | 0.6 | 108 |
| 39 | Extrapulmonary Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 083-101. | 0.8 | 107 |
| 40 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF INFlixIMAB IN PATIENTS WITH CHRONIC PULMONARY SARCOIDOSIS. <i>Chest</i> , 2005, 128, 202S. | 0.4 | 106 |
| 41 | Genome-wide search for sarcoidosis susceptibility genes in African Americans. <i>Genes and Immunity</i> , 2005, 6, 509-518. | 2.2 | 106 |
| 42 | Disease Burden and Variability in Sarcoidosis. <i>Annals of the American Thoracic Society</i> , 2017, 14, S421-S428. | 1.5 | 106 |
| 43 | The Sarcoidosis Health Questionnaire. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 323-329. | 2.5 | 102 |
| 44 | Neurosarcoidosis: Clinical manifestations, diagnosis and treatment. <i>Presse Medicale</i> , 2012, 41, e331-e348. | 0.8 | 102 |
| 45 | The effect of corticosteroids on quality of life in a sarcoidosis clinic: The results of a propensity analysis. <i>Respiratory Medicine</i> , 2015, 109, 526-531. | 1.3 | 101 |
| 46 | Pleural Effusions in a Series of 181 Outpatients With Sarcoidosis. <i>Chest</i> , 2006, 129, 1599-1604. | 0.4 | 99 |
| 47 | Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy. <i>Chest</i> , 2009, 136, 526-535. | 0.4 | 98 |
| 48 | Job and Industry Classifications Associated With Sarcoidosis in a Caseâ€“Control Etiologic Study of Sarcoidosis (ACCESS). <i>Journal of Occupational and Environmental Medicine</i> , 2005, 47, 226-234. | 0.9 | 95 |
| 49 | Efficacy of Short-Course, Low-Dose Corticosteroid Therapy for Acute Pulmonary Sarcoidosis Exacerbations. <i>American Journal of the Medical Sciences</i> , 2010, 339, 1-4. | 0.4 | 93 |
| 50 | Efficacy and Safety of Apremilast in Chronic Cutaneous Sarcoidosis. <i>Archives of Dermatology</i> , 2012, 148, 262. | 1.7 | 90 |
| 51 | Pathophysiology and clinical management of cardiac sarcoidosis. <i>Nature Reviews Cardiology</i> , 2015, 12, 278-288. | 6.1 | 89 |
| 52 | Airway Obstruction Arising From Blood Clot. <i>Chest</i> , 1999, 115, 293-300. | 0.4 | 88 |
| 53 | Spinal Cord Neurosarcoidosis. <i>American Journal of the Medical Sciences</i> , 2014, 347, 195-198. | 0.4 | 84 |
| 54 | Chronic cutaneous lesions of sarcoidosis. <i>Clinics in Dermatology</i> , 2007, 25, 295-302. | 0.8 | 83 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Sarcoidosis: Clinical Presentation, Diagnosis, and Approach to Treatment. American Journal of the Medical Sciences, 2008, 335, 26-33. | 0.4 | 81 |
| 56 | Cellular Responses to Mycobacterial Antigens Are Present in Bronchoalveolar Lavage Fluid Used in the Diagnosis of Sarcoidosis. Infection and Immunity, 2009, 77, 3740-3748. | 1.0 | 80 |
| 57 | A Modern Series of Percutaneous Intracavitary Instillation of Amphotericin B for the Treatment of Severe Hemoptysis From Pulmonary Aspergilloma. Chest, 2013, 143, 1414-1421. | 0.4 | 78 |
| 58 | Biomarkers in sarcoidosis. Expert Review of Clinical Immunology, 2016, 12, 1191-1208. | 1.3 | 77 |
| 59 | Organizing Pneumonia. American Journal of the Medical Sciences, 2008, 335, 34-39. | 0.4 | 76 |
| 60 | Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. International Journal of Cardiology, 2017, 227, 565-570. | 0.8 | 76 |
| 61 | Hepatic, Splenic, and Gastrointestinal Involvement with Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 529-542. | 0.8 | 74 |
| 62 | A Current Assessment of Rurally Linked Exposures as Potential Risk Factors for Sarcoidosis. Annals of Epidemiology, 2001, 11, 111-117. | 0.9 | 73 |
| 63 | Sarcoidosis: social predictors of severity at presentation. European Respiratory Journal, 2004, 24, 601-608. | 3.1 | 73 |
| 64 | Is endosonography guided fine needle aspiration (EUS-FNA) for sarcoidosis as good as we think?. Thorax, 2004, 59, 794-799. | 2.7 | 72 |
| 65 | Molecular profiling and gene expression analysis in cutaneous sarcoidosis: The role of interleukin-12, interleukin-23, and the T-helper 17 pathway. Journal of the American Academy of Dermatology, 2012, 66, 901-910.e2. | 0.6 | 71 |
| 66 | Endobronchial Lesions in HIV-infected Individuals. Chest, 1994, 105, 1314-1323. | 0.4 | 69 |
| 67 | Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement. Chest, 2018, 154, 349-356. | 0.4 | 68 |
| 68 | Relationship of Environmental Exposures to the Clinical Phenotype of Sarcoidosis. Chest, 2005, 128, 207-215. | 0.4 | 67 |
| 69 | The treatment of pulmonary sarcoidosis. Respiratory Medicine, 2012, 106, 1351-1361. | 1.3 | 67 |
| 70 | Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respiriology, 2009, 14, 522-528. | 1.3 | 66 |
| 71 | Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respiratory Medicine, 2008, 102, 1636-1642. | 1.3 | 61 |
| 72 | Acute Pulmonary Exacerbations of Sarcoidosis. Chest, 2012, 142, 827-836. | 0.4 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Neurosarcoidosis. Current Treatment Options in Neurology, 2013, 15, 492-504. | 0.7 | 61 |
| 74 | Endoscopic Ultrasonography with Fine-Needle Aspiration: An Accurate and Simple Diagnostic Modality for Sarcoidosis. Endoscopy, 1999, 31, 377-382. | 1.0 | 57 |
| 75 | Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 955-964. | 2.5 | 57 |
| 76 | A New Tool To Assess Sarcoidosis Severity. Chest, 2006, 129, 1234-1245. | 0.4 | 56 |
| 77 | Cutaneous Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 442-451. | 0.8 | 56 |
| 78 | Sarcoidosis. Medical Clinics of North America, 2005, 89, 817-828. | 1.1 | 54 |
| 79 | Racial and Ethnic Disparities in Sarcoidosis: From Genetics to Socioeconomics. Clinics in Chest Medicine, 2006, 27, 453-462. | 0.8 | 54 |
| 80 | Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2002, 19, 198-204. | 0.2 | 54 |
| 81 | ICU Admission Muscle and Fat Mass, Survival, and Disability at Discharge. Chest, 2019, 155, 322-330. | 0.4 | 53 |
| 82 | Neurological Deficits During Treatment With Tumor Necrosis Factor-Alpha Antagonists. American Journal of the Medical Sciences, 2011, 342, 352-355. | 0.4 | 52 |
| 83 | Allergic Bronchopulmonary Aspergillosis. Clinics in Chest Medicine, 2012, 33, 265-281. | 0.8 | 52 |
| 84 | Isolated Neurosarcoidosis. Neurologist, 2012, 18, 373-377. | 0.4 | 51 |
| 85 | Environmental Risk Factors for Sarcoidosis. Frontiers in Immunology, 2020, 11, 1340. | 2.2 | 49 |
| 86 | Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Design, Development and Therapy, 2013, 7, 325. | 2.0 | 48 |
| 87 | Validation and Important Differences for the Sarcoidosis Assessment Tool. A New Patient-reported Outcome Measure. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 786-795. | 2.5 | 48 |
| 88 | Pneumothorax in critically ill patients with COVID-19 infection: Incidence, clinical characteristics and outcomes in a case control multicenter study. Respiratory Medicine, 2021, 184, 106464. | 1.3 | 48 |
| 89 | Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 147-53. | 0.2 | 48 |
| 90 | New advances in the management of pulmonary sarcoidosis. BMJ: British Medical Journal, 2019, 367, 15553. | 2.4 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Chronic Facial Sarcoidosis Including Lupus Pernio. American Journal of Clinical Dermatology, 2008, 9, 155-161. | 3.3 | 45 |
| 92 | Corticosteroids in Sarcoidosis. Rheumatic Disease Clinics of North America, 2016, 42, 119-135. | 0.8 | 45 |
| 93 | Pleural Effusions Following Lung Transplantation. Chest, 1996, 109, 1190-1194. | 0.4 | 44 |
| 94 | Inflammatory Profile and Response to Anti-Tumor Necrosis Factor Therapy in Patients with Chronic Pulmonary Sarcoidosis. Vaccine Journal, 2011, 18, 931-939. | 3.2 | 44 |
| 95 | Bullous Sarcoidosis. Chest, 1998, 114, 1474-1478. | 0.4 | 43 |
| 96 | Comparison of Sarcoidosis Phenotypes Among Affected African-American Siblings. Chest, 2006, 130, 855-862. | 0.4 | 43 |
| 97 | Advances in the diagnosis and treatment of sarcoidosis. F1000prime Reports, 2014, 6, 89. | 5.9 | 43 |
| 98 | Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters. Chest, 2018, 153, 114-123. | 0.4 | 43 |
| 99 | COMPLICATIONS OF VIDEO ASSISTED THORACOSCOPIC LUNG BIOPSY IN PATIENTS WITH INTERSTITIAL LUNG DISEASE. Chest, 2005, 128, 168S. | 0.4 | 41 |
| 100 | The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis. Respiriology, 2008, 13, 97-102. | 1.3 | 41 |
| 101 | Relapses of sarcoidosis: what are they and can we predict who will get them?. European Respiratory Journal, 2014, 43, 337-339. | 3.1 | 41 |
| 102 | Interrelationship Between Sleep-Disordered Breathing and Sarcoidosis. Chest, 2015, 148, 1105-1114. | 0.4 | 40 |
| 103 | Primary Pulmonary Involvement of Fusarium solani in a Lung Transplant Recipient. Chest, 1997, 112, 1128-1130. | 0.4 | 39 |
| 104 | Clinical phenotypes in sarcoidosis. Current Opinion in Pulmonary Medicine, 2014, 20, 496-502. | 1.2 | 39 |
| 105 | The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: A retrospective analysis from a randomized clinical trial. Respiratory Medicine, 2014, 108, 189-194. | 1.3 | 39 |
| 106 | A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 115-22. | 0.2 | 38 |
| 107 | Low Levels of NF- κ B/p65 Mark Anergic CD4 + T Cells and Correlate with Disease Severity in Sarcoidosis. Vaccine Journal, 2011, 18, 223-234. | 3.2 | 37 |
| 108 | The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?. Respiratory Medicine, 2015, 109, 557-564. | 1.3 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | The three tiers of screening for sarcoidosis organ involvement. <i>Respiratory Medicine</i> , 2016, 113, 42-49. | 1.3 | 36 |
| 110 | When the Game Changes. <i>Chest</i> , 2020, 158, 892-895. | 0.4 | 36 |
| 111 | Diagnostic Accuracy of Thoracic Ultrasonography to Differentiate Transudative From Exudative Pleural Effusion. <i>Chest</i> , 2020, 158, 692-697. | 0.4 | 35 |
| 112 | Successful Treatment of Widely Disseminated Acanthamoebiasis. <i>Southern Medical Journal</i> , 1999, 92, 55-57. | 0.3 | 34 |
| 113 | ICU admission body composition: skeletal muscle, bone, and fat effects on mortality and disability at hospital discharge—a prospective, cohort study. <i>Critical Care</i> , 2020, 24, 566. | 2.5 | 34 |
| 114 | Pneumoperitoneum to Treat Air Leaks and Spaces After a Lung Volume Reduction Operation. <i>Annals of Thoracic Surgery</i> , 1997, 64, 1803-1805. | 0.7 | 32 |
| 115 | A Case Report of a Dactylaria Fungal Infection in a Lung Transplant Patient. <i>Chest</i> , 2001, 119, 651-653. | 0.4 | 32 |
| 116 | Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. <i>Heart</i> , 2016, 102, 411-414. | 1.2 | 32 |
| 117 | Allergic Bronchopulmonary Aspergillosis After Infliximab Therapy for Sarcoidosis. <i>Chest</i> , 2009, 135, 1358-1359. | 0.4 | 31 |
| 118 | Impact of Systemic Corticosteroids on Healthcare Utilization in Patients With Sarcoidosis. <i>American Journal of the Medical Sciences</i> , 2011, 341, 196-201. | 0.4 | 31 |
| 119 | Quality of Life in Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 546-558. | 0.8 | 31 |
| 120 | Diagnosis of pulmonary Kaposi's sarcoma with fiberoptic bronchoscopy and endobronchial biopsy. A report of five cases. <i>Cancer</i> , 1987, 59, 807-810. | 2.0 | 30 |
| 121 | Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. <i>Diagnostics</i> , 2021, 11, 1089. | 1.3 | 30 |
| 122 | The spectrum of biopsy sites for the diagnosis of sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2005, 22, 139-46. | 0.2 | 30 |
| 123 | Elevated MicroRNA-33 in Sarcoidosis and a Carbon Nanotube Model of Chronic Granulomatous Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 865-871. | 1.4 | 28 |
| 124 | Clinical Manifestations, Radiographic Findings, Treatment Options, and Outcome in Sarcoidosis Patients with Upper Respiratory Tract Involvement. <i>Southern Medical Journal</i> , 2010, 103, 870-875. | 0.3 | 26 |
| 125 | A conceptual model of health-related quality of life in sarcoidosis. <i>Quality of Life Research</i> , 2014, 23, 89-101. | 1.5 | 26 |
| 126 | Pulmonary Physiologic Abnormalities Caused by Pleural Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1995, 16, 346-353. | 0.8 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Pleural Effusion From Acute Lung Rejection. <i>Chest</i> , 1997, 111, 1128-1130. | 0.4 | 25 |
| 128 | Is There an Anatomic Explanation for Chest Pain in Patients With Pulmonary Sarcoidosis?. <i>Southern Medical Journal</i> , 1997, 90, 911-914. | 0.3 | 25 |
| 129 | The "Fairy Ring". <i>Chest</i> , 1999, 115, 275-276. | 0.4 | 25 |
| 130 | Range of the Fractional Weak Discrepancy Function. <i>Order</i> , 2006, 23, 51-63. | 0.3 | 25 |
| 131 | Valproic Acid-Induced Eosinophilic Pleural Effusion: A Case Report and Review of the Literature. <i>American Journal of the Medical Sciences</i> , 2007, 333, 290-292. | 0.4 | 25 |
| 132 | Concomitant sarcoidosis and a connective tissue disease: Review of the clinical findings and postulations concerning their association. <i>Respiratory Medicine</i> , 2013, 107, 1453-1459. | 1.3 | 25 |
| 133 | Strategies for identifying pulmonary sarcoidosis patients at risk for severe or chronic disease. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 111-118. | 1.0 | 25 |
| 134 | Noninvasive Aspergillus Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2004, 25, 203-219. | 0.8 | 24 |
| 135 | Distinguishing Asthma from Sarcoidosis: An Approach to a Problem that is not Always Solvable. <i>Journal of Asthma</i> , 2013, 50, 1-6. | 0.9 | 24 |
| 136 | The diagnosis of sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 484-496. | 1.2 | 24 |
| 137 | The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study. <i>Respiratory Medicine</i> , 2021, 187, 106564. | 1.3 | 24 |
| 138 | Sarcoidosis Associated With an Elevated Serum CA 125 Level: Description of a Case and a Review of the Literature. <i>American Journal of the Medical Sciences</i> , 2007, 334, 441-443. | 0.4 | 23 |
| 139 | Intracavitary voriconazole for the treatment of hemoptysis complicating <i>Pseudallescheria angusta</i> pulmonary mycetomas in fibrocystic sarcoidosis. <i>Medical Mycology</i> , 2011, 49, 198-201. | 0.3 | 23 |
| 140 | Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis. <i>Chest</i> , 2021, 159, 1902-1912. | 0.4 | 23 |
| 141 | Current pharmacotherapy of allergic bronchopulmonary aspergillosis. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 1065-1071. | 0.9 | 22 |
| 142 | How are cancer and connective tissue diseases related to sarcoidosis?. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 517-524. | 1.2 | 22 |
| 143 | Rieske iron-sulfur protein induces FKBP12.6/RyR2 complex remodeling and subsequent pulmonary hypertension through NF- κ B/cyclin D1 pathway. <i>Nature Communications</i> , 2020, 11, 3527. | 5.8 | 22 |
| 144 | The Etiologic Agent of Sarcoidosis. <i>Chest</i> , 2003, 124, 6-8. | 0.4 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2021, 320, R250-R257. | 0.9 | 21 |
| 146 | The indications for the treatment of sarcoidosis: Wells Law. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 280-282. | 0.2 | 21 |
| 147 | Management of Advanced Pulmonary Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 495-506. | 2.5 | 21 |
| 148 | Quality of Life Assessment in Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015, 36, 739-750. | 0.8 | 20 |
| 149 | The Relationship of Pleural Manometry With Postthoracentesis Chest Radiographic Findings in Malignant Pleural Effusion. <i>Chest</i> , 2020, 157, 421-426. | 0.4 | 20 |
| 150 | Granulomatous Sarcoidosis Mimics. <i>Frontiers in Medicine</i> , 2021, 8, 680989. | 1.2 | 20 |
| 151 | How many organs need to be involved to diagnose sarcoidosis?: An unanswered question that, hopefully, will become irrelevant. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014, 31, 6-7. | 0.2 | 20 |
| 152 | Quality of life evaluation in sarcoidosis: current status and future directions. <i>Current Opinion in Pulmonary Medicine</i> , 2008, 14, 470-477. | 1.2 | 19 |
| 153 | Sarcoidosis Presenting as Bilateral Vocal Cord Paralysis From Bilateral Compression of the Recurrent Laryngeal Nerves From Thoracic Adenopathy. <i>Journal of Voice</i> , 2009, 23, 631-634. | 0.6 | 18 |
| 154 | Successful Treatment of Lupus Pernio With Adalimumab. <i>Archives of Dermatology</i> , 2011, 147, 1332. | 1.7 | 18 |
| 155 | Paradoxical Reactions and the Immune Reconstitution Inflammatory Syndrome. <i>Microbiology Spectrum</i> , 2017, 5, . | 1.2 | 18 |
| 156 | Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, e2020009. | 0.2 | 18 |
| 157 | The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2005, 22, 235. | 0.2 | 18 |
| 158 | Mycobacterium scrofulaceum Infection Presenting as Lung Nodules in a Heart Transplant Recipient. <i>Chest</i> , 1994, 106, 1918-1920. | 0.4 | 17 |
| 159 | Carbon Nanotubes and Chronic Granulomatous Disease. <i>Nanomaterials</i> , 2014, 4, 508-521. | 1.9 | 17 |
| 160 | The role of serum amyloid A staining of granulomatous tissues for the diagnosis of sarcoidosis. <i>Respiratory Medicine</i> , 2017, 126, 1-8. | 1.3 | 17 |
| 161 | The Management of Sarcoidosis by the Primary Care Physician. <i>American Journal of Medicine</i> , 2007, 120, 403-407. | 0.6 | 16 |
| 162 | Small fiber neuropathy in sarcoidosis: Something beneath the surface. <i>Respiratory Medicine</i> , 2011, 105, 1-2. | 1.3 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Clinical aspects of portopulmonary hypertension. <i>Respiratory Medicine</i> , 2014, 108, 943-954. | 1.3 | 16 |
| 164 | Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis. <i>Quality of Life Research</i> , 2014, 23, 1301-1313. | 1.5 | 16 |
| 165 | Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis. <i>Respiratory Medicine</i> , 2019, 152, 14-19. | 1.3 | 16 |
| 166 | Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study. <i>Annals of the American Thoracic Society</i> , 2021, 18, 477-485. | 1.5 | 16 |
| 167 | COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities. <i>Frontiers in Medicine</i> , 2021, 8, 672028. | 1.2 | 16 |
| 168 | Pneumothorax and Bronchopleural Fistula During Treatment of Allergic Bronchopulmonary Aspergillosis. <i>Southern Medical Journal</i> , 1993, 86, 1061-1063. | 0.3 | 15 |
| 169 | Refractory Hypotension Associated With Hypocalcemia and Renal Disease. <i>American Journal of Kidney Diseases</i> , 1994, 23, 430-432. | 2.1 | 15 |
| 170 | Highly Active Antiretroviral Therapy for HIV With Tuberculosis. <i>Chest</i> , 2002, 122, 399-400. | 0.4 | 15 |
| 171 | Pleural Effusion Caused by Trapped Lung. <i>Southern Medical Journal</i> , 2003, 96, 510-511. | 0.3 | 15 |
| 172 | The Assessment of Cough in a Sarcoidosis Clinic Using a Validated instrument and a Visual Analog Scale. <i>Lung</i> , 2017, 195, 587-594. | 1.4 | 15 |
| 173 | Patient perspectives in sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 478-483. | 1.2 | 15 |
| 174 | Cardiac Sarcoidosis. <i>Chest</i> , 2005, 128, 3-6. | 0.4 | 14 |
| 175 | A proposed solution to the clinical assessment of sarcoidosis: The sarcoidosis three-dimensional assessment instrument (STAI). <i>Medical Hypotheses</i> , 2007, 68, 1080-1087. | 0.8 | 14 |
| 176 | Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009203. | 2.1 | 14 |
| 177 | Screening sarcoidosis patients for cardiac sarcoidosis: What the data really show. <i>Respiratory Medicine</i> , 2019, 154, 155-157. | 1.3 | 13 |
| 178 | Chylothorax in a Patient With AIDS and Kaposi's Sarcoma. <i>Southern Medical Journal</i> , 1990, 83, 322-324. | 0.3 | 12 |
| 179 | Bird-Years as Well as Pack-Years. <i>Chest</i> , 2004, 125, 353-354. | 0.4 | 12 |
| 180 | The pressure-dependent air leak after partial lung resection. <i>Thorax</i> , 2017, 72, 290-291. | 2.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | The Diagnosis of Sarcoidosis. Chest, 2018, 154, 1006-1007. | 0.4 | 12 |
| 182 | Novel ACE mutations mimicking sarcoidosis by increasing blood ACE levels. Translational Research, 2021, 230, 5-20. | 2.2 | 12 |
| 183 | Mediastinal Lymphadenopathy in Patients Undergoing Cardiac Transplant Evaluation. Chest, 2011, 139, 1451-1457. | 0.4 | 11 |
| 184 | Worsening of pulmonary sarcoidosis. Current Opinion in Pulmonary Medicine, 2014, 20, 508-516. | 1.2 | 11 |
| 185 | Granulomatous lung disease: clinical aspects. Expert Review of Respiratory Medicine, 2020, 14, 1045-1063. | 1.0 | 11 |
| 186 | Therapeutic strategies for pulmonary sarcoidosis. Expert Review of Respiratory Medicine, 2020, 14, 391-403. | 1.0 | 11 |
| 187 | Coexistent Takayasu arteritis and sarcoidosis: a case report and review of the literature. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2019, 36, 311-317. | 0.2 | 11 |
| 188 | Status Asthmaticus With Acute Decompensation With Therapy in a 27-Year-Old Woman. Chest, 1995, 107, 563-565. | 0.4 | 10 |
| 189 | Patient-Reported Outcome Measures for Sleep Disorders and Related Problems. Chest, 2013, 143, 1809-1818. | 0.4 | 10 |
| 190 | Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis. Nuclear Medicine Communications, 2016, 37, 273-277. | 0.5 | 10 |
| 191 | Sevoflurane Induced Diffuse Alveolar Hemorrhage in a young patient. Respiratory Medicine Case Reports, 2017, 20, 14-15. | 0.2 | 10 |
| 192 | Responsiveness to Change and Establishment of the Minimal Clinically Important Difference for the Cutaneous Sarcoidosis Activity and Morphology Instrument. JAMA Dermatology, 2020, 156, 98. | 2.0 | 10 |
| 193 | Association between Drainage-Dependent Prolonged Air Leak after Partial Lung Resection and Clinical Outcomes: A Prospective Cohort Study. Annals of the American Thoracic Society, 2022, 19, 389-398. | 1.5 | 10 |
| 194 | Treatment of a Solitary Pulmonary Sarcoidosis Mass by CT-Guided Direct Intralesional Injection of Corticosteroid. Chest, 2001, 120, 316-317. | 0.4 | 9 |
| 195 | Reply to: Monogenic early-onset sarcoidosis is no longer a variant of "idiopathic" sarcoidosis. Journal of the American Academy of Dermatology, 2013, 69, 165. | 0.6 | 9 |
| 196 | The value of sound waves and pleural manometry in diagnosing a pleural effusion with the dual diagnosis. Thorax, 2016, 71, 1064-1065. | 2.7 | 9 |
| 197 | A sarcoidosis clinician's perspective of MHC functional elements outside the antigen binding site. Human Immunology, 2019, 80, 85-89. | 1.2 | 9 |
| 198 | Screening Sarcoidosis Patients for Occult Disease. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 741-757. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Corticosteroid refractory sarcoidosis. <i>Respiratory Medicine</i> , 2020, 171, 106081. | 1.3 | 9 |
| 200 | Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). <i>Respiratory Medicine</i> , 2022, 191, 106436. | 1.3 | 9 |
| 201 | High frequency ultrasound: a novel instrument to quantify granuloma burden in cutaneous sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 136-141. | 0.2 | 9 |
| 202 | Vaginal Involvement in a Patient With Sarcoidosis. <i>Chest</i> , 2010, 137, 455-456. | 0.4 | 8 |
| 203 | Rapid Development of Sarcoid Tenosynovitis. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 201-203. | 0.5 | 8 |
| 204 | A Delphi Study of Pharmacotherapy for Noncystic Fibrosis Bronchiectasis. <i>American Journal of the Medical Sciences</i> , 2014, 348, 387-393. | 0.4 | 8 |
| 205 | The development of sarcoidosis in patients receiving daclizumab: A case series from multiple clinical trials. <i>Respiratory Medicine</i> , 2019, 149, 23-27. | 1.3 | 8 |
| 206 | Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns. <i>F1000Research</i> , 2019, 8, 2149. | 0.8 | 8 |
| 207 | Staple Metalloptysis After Lung Resection for Mycetoma: A Case Report and a Review of the Literature. <i>American Journal of the Medical Sciences</i> , 2008, 336, 365-367. | 0.4 | 7 |
| 208 | Endpoints in sarcoidosis: More like IPF or asthma?. <i>Respiratory Medicine</i> , 2018, 138, S3-S4. | 1.3 | 7 |
| 209 | The epidemic of drug-induced sarcoidosis-like reactions: a side effect that we can live with. <i>Journal of Internal Medicine</i> , 2020, 288, 373-375. | 2.7 | 7 |
| 210 | Sarcoidosis associated pleural effusion: Clinical aspects. <i>Respiratory Medicine</i> , 2022, 191, 106723. | 1.3 | 7 |
| 211 | Origin of Pleural Cells After Lung Transplantation*. <i>Chest</i> , 1997, 112, 426-429. | 0.4 | 6 |
| 212 | ASSESSMENT OF INFlixIMAB EFFICACY IN EXTRAPULMONARY SARCOIDOSIS USING A NOVEL ASSESSMENT TOOL: RESULTS FROM A RANDOMIZED TRIAL. <i>Chest</i> , 2005, 128, 202S. | 0.4 | 6 |
| 213 | Readdressing the entity of exercise pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2017, 124, 65-71. | 1.3 | 6 |
| 214 | Blastomycosis in the Capital District of New York State: A Newly Identified Emerging Endemic Area. <i>American Journal of Medicine</i> , 2021, 134, e101-e108. | 0.6 | 6 |
| 215 | Quality of Life and Physical Activity in 629 Individuals With Sarcoidosis: Prospective, Cross-sectional Study Using Smartphones (Sarcoidosis App). <i>JMIR MHealth and UHealth</i> , 2022, 10, e38331. | 1.8 | 6 |
| 216 | Unusual Presentations of Pulmonary Sarcoidosis: Cases from the Medical University of South Carolina. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 075-082. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Assessment of Mediastinal Lymph Node Size in Pneumococcal Pneumonia with Bacteremia. <i>Lung</i> , 2018, 196, 43-48. | 1.4 | 5 |
| 218 | Rare case of parathyroid gland sarcoidosis presenting with hypercalcaemia. <i>BMJ Case Reports</i> , 2019, 12, e230598. | 0.2 | 5 |
| 219 | Inflammatory Pathways in Sarcoidosis. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1304, 39-52. | 0.8 | 5 |
| 220 | Management of immunosuppressants in the era of coronavirus disease-2019. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 176-183. | 1.2 | 5 |
| 221 | Antifibrotic drugs for pulmonary sarcoidosis: A treatment in search of an indication. <i>Respiratory Medicine</i> , 2021, 180, 106371. | 1.3 | 5 |
| 222 | The Relationship of Obesity and OSA to the Development of Sarcoidosis. <i>Chest</i> , 2022, 162, 1086-1092. | 0.4 | 5 |
| 223 | <i>Pneumocystis carinii</i> Pneumonia Manifested as Hilar Mass and Cavitory Lesion: An Atypical Presentation in a Patient Receiving Aerosolized Pentamidine Prophylaxis. <i>Southern Medical Journal</i> , 1990, 83, 1309-1312. | 0.3 | 4 |
| 224 | Lupus Pernio or Chilblain Lupus?: Response. <i>Chest</i> , 2009, 136, 947. | 0.4 | 4 |
| 225 | Lung Transplantation for Sarcoidosis. <i>Lung Biology in Health and Disease</i> , 2005, , 745-767. | 0.1 | 4 |
| 226 | Roflumilast (Daliresp [®]) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021035. | 0.2 | 4 |
| 227 | Granulomatosis and Polyangitis Followed by Alveolar Proteinosis in a 32-Year-Old Woman. <i>Chest</i> , 2012, 141, 1359-1360. | 0.4 | 3 |
| 228 | Infliximab-Induced Hypothyroidism: A Novel Case and Postulations concerning the Mechanism. <i>Case Reports in Medicine</i> , 2013, 2013, 1-2. | 0.3 | 3 |
| 229 | Reply to Bauer and Goff. <i>Clinical Infectious Diseases</i> , 2015, 61, 487-488. | 2.9 | 3 |
| 230 | <i>Pasteurella multocida</i> pleural effusion: A case report and review of literature. <i>Respiratory Medicine Case Reports</i> , 2016, 19, 68-70. | 0.2 | 3 |
| 231 | Causes of Poor Medication Adherence in Sarcoidosis. <i>Chest</i> , 2020, 158, 17-18. | 0.4 | 3 |
| 232 | Corticosteroid-Sparing Drugs in Sarcoidosis: How Should We Assess Them?. <i>Lung</i> , 2021, 199, 85-86. | 1.4 | 3 |
| 233 | A Primer on the Clinical Aspects of Sarcoidosis for the Basic and Translational Scientist. <i>Journal of Clinical Medicine</i> , 2021, 10, 2857. | 1.0 | 3 |
| 234 | The treatment of sarcoidosis: translating the European respiratory guidelines into clinical practice. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 451-460. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | A 74-year-old Man With Chronic Lymphocytic Leukemia, Cough, and a Lung Mass. <i>Chest</i> , 1999, 116, 1798-1801. | 0.4 | 2 |
| 236 | Pharyngitis, Splenomegaly, and Hilar and Peripheral Adenopathy in a 29-Year-Old Man With Acute Hypoxic Respiratory Failure. <i>Chest</i> , 2001, 119, 1586-1589. | 0.4 | 2 |
| 237 | Diagnosis and treatment of allergic bronchopulmonary aspergillosis. <i>Current Fungal Infection Reports</i> , 2008, 2, 199-205. | 0.9 | 2 |
| 238 | Tuberculous mediastinal lymphadenitis that evolved into pulmonary tuberculosis following transbronchial needle aspiration. <i>Respirology</i> , 2010, 15, 1140-1141. | 1.3 | 2 |
| 239 | Sarcoidosis: Lost in translation. <i>Respirology</i> , 2011, 16, 384-385. | 1.3 | 2 |
| 240 | Chronic Hypoxemia and Paraganglioma: A Rare Case and Discussion of Potential Mechanisms. <i>American Journal of the Medical Sciences</i> , 2014, 348, 528-529. | 0.4 | 2 |
| 241 | Determining the cause of pulmonary granulomas: A multidimensional process. <i>Respirology</i> , 2015, 20, 5-6. | 1.3 | 2 |
| 242 | Effect of SSRIs and SNRIs on Nocturnal Urinary Frequency. <i>Annals of Pharmacotherapy</i> , 2016, 50, 471-474. | 0.9 | 2 |
| 243 | Emerging and potential treatment options for sarcoidosis. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 17-33. | 0.5 | 2 |
| 244 | The time bomb of isolated cardiac sarcoidosis: Is it ticking?. <i>International Journal of Cardiology</i> , 2022, 347, 62-63. | 0.8 | 2 |
| 245 | The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP). <i>Respiratory Medicine</i> , 2022, 196, 106819. | 1.3 | 2 |
| 246 | Tissue verification of stage I sarcoidosis: the question is if, not how. <i>Chest</i> , 2008, 133, 1529-1530. | 0.4 | 2 |
| 247 | Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021034. | 0.2 | 2 |
| 248 | Dysphagia From Thoracostomy Tube Compression of the Esophagus After Single Lung Transplantation. <i>Southern Medical Journal</i> , 1996, 89, 249-250. | 0.3 | 1 |
| 249 | Concomitant Acute Sinusitis and Acute Lung Rejection. <i>Southern Medical Journal</i> , 2000, 93, 223-225. | 0.3 | 1 |
| 250 | A Neutropenic Patient With Rapidly Progressive Lung Lesion. <i>Chest</i> , 2004, 126, 1364-1367. | 0.4 | 1 |
| 251 | Lupus Pernio Activity and Severity Index (LuPASI) Score in Sarcoidosis Patients. <i>Chest</i> , 2004, 126, 891S. | 0.4 | 1 |
| 252 | Trouble Below the Surface. <i>American Journal of Medicine</i> , 2006, 119, 828-831. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 253 | SARCOIDOSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (SAPAH): CHARACTERISTICS OF PATIENTS ENROLLED IN A PROSPECTIVE, OPEN LABEL TRIAL OF INHALED ILOPROST. <i>Chest</i> , 2007, 132, 482A. | 0.4 | 1 |
| 254 | Intracavitary Voriconazole For Symptomatic <i>Pseudallescheria Boydii</i> Pulmonary Mycetomas In A Patient With Fibrocystic Sarcoidosis. , 2010, , . | | 1 |
| 255 | Intracavitary Amphotericin B For Pulmonary Aspergilloma Complicated By Serious Hemoptysis In Fibrocystic Sarcoidosis. , 2010, , . | | 1 |
| 256 | A 23-Year-Old Man With Recurrent Hemoptysis. <i>Chest</i> , 2015, 148, e152-e155. | 0.4 | 1 |
| 257 | A Bare-Bones Approach. <i>New England Journal of Medicine</i> , 2017, 376, 1371-1376. | 13.9 | 1 |
| 258 | A necrotic tonsillar lesion: An unusual presentation of disseminated histoplasmosis. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 44-46. | 0.2 | 1 |
| 259 | Respiratory Medicine: Focus on Sarcoidosis: Editor's welcome. <i>Respiratory Medicine</i> , 2018, 138, S1-S2. | 1.3 | 1 |
| 260 | Considerations regarding sarcoidosis in the bariatric surgical patient. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 219-224. | 1.0 | 1 |
| 261 | Monitoring cardiac sarcoidosis: The next frontier. <i>Respiratory Medicine</i> , 2018, 144, S5-S6. | 1.3 | 1 |
| 262 | Parasarcoidosis Syndromes. , 2019, , 167-177. | | 1 |
| 263 | Assessing the reliability of obstructive sleep apnea screening instruments in isolation or in combination. <i>Respiratory Medicine: X</i> , 2020, 2, 100019. | 1.4 | 1 |
| 264 | RESPONDER ANALYSES IN PATIENTS RECEIVING INFLIXIMAB FOR CHRONIC SARCOIDOSIS WITH PULMONARY INVOLVEMENT. <i>Chest</i> , 2005, 128, 316S. | 0.4 | 1 |
| 265 | Acute Pulmonary Exacerbation of Sarcoidosis. , 2014, , 65-78. | | 1 |
| 266 | Proteinuria in sarcoidosis: Prevalence and risk factors in a consecutive outpatient cohort. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 142-148. | 0.2 | 1 |
| 267 | Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 165-169. | 0.2 | 1 |
| 268 | The ability to predict the clinical course of pulmonary sarcoidosis from data that is right in front of us. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220012. | 0.4 | 1 |
| 269 | Estimation of Auto-PEEP. <i>Chest</i> , 1991, 99, 519. | 0.4 | 0 |
| 270 | It's Not "Just a Virus" Anymore. <i>Chest</i> , 1998, 113, 859-860. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | DIAGNOSIS OF PULMONARY SARCOIDOSIS USING ENDOBRONCHIAL ULTRASONOGRAPHY WITH TRANSBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA) AS A PRIMARY DIAGNOSTIC MODALITY. Chest, 2006, 130, 111S. | 0.4 | 0 |
| 272 | Sarcoidosis: Evolving Concepts and Controversies. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 001-002. | 0.8 | 0 |
| 273 | Dyspnea Originating Far From the Heart and Lung. Chest, 2015, 148, 860A. | 0.4 | 0 |
| 274 | Serum Amyloid a Immunostaining of Granulomatous Tissue as a Novel Diagnostic Test for Sarcoidosis. Chest, 2016, 150, 788A. | 0.4 | 0 |
| 275 | Allergic bronchopulmonary aspergillosis: what's known and what's new. Current Pulmonology Reports, 2016, 5, 177-183. | 0.5 | 0 |
| 276 | Predictors of Cardiac Decompensation in Patients With Cardiac Sarcoidosis Undergoing De-escalation of Treatment. Chest, 2017, 152, A73. | 0.4 | 0 |
| 277 | Paradoxical Reactions and the Immune Reconstitution Inflammatory Syndrome. , 0, , 637-652. | | 0 |
| 278 | Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. Open Forum Infectious Diseases, 2017, 4, S52-S52. | 0.4 | 0 |
| 279 | Sarcoidosis: Advances in Therapy. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 605-606. | 0.8 | 0 |
| 280 | Response. Chest, 2020, 158, 1783-1784. | 0.4 | 0 |
| 281 | The Reply. American Journal of Medicine, 2020, 133, e206-e207. | 0.6 | 0 |
| 282 | Editorial: Novel Insights Into the Immunology of Pulmonary Granulomatous Diseases. Frontiers in Immunology, 2020, 11, 633103. | 2.2 | 0 |
| 283 | Response. Chest, 2021, 159, 1307-1308. | 0.4 | 0 |
| 284 | The Treatment of ABPA. , 2009, , 747-759. | | 0 |
| 285 | The Diagnosis of Sarcoidosis. , 2014, , 1-18. | | 0 |
| 286 | Physician Mistrust and Discrimination in Sarcoidosis: It's Real and It's Prevalent. Annals of the American Thoracic Society, 2021, 18, 1781-1783. | 1.5 | 0 |
| 287 | Repository corticotropin injection (H.P. Acthar gel) for the treatment of sarcoidosis-induced hypercalciuria and vitamin D dysregulation: a pilot, open label study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 192-197. | 0.2 | 0 |
| 288 | The manifestations of rare organ sarcoidosis. , 2022, , 295-315. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|----|-----------|
| 289 | Quality-of-life assessment in patients with sarcoidosis. , 2022, , 337-349. | | 0 |